Mesoblast (MESO) Change in Account Payables (2014 - 2024)
Mesoblast (MESO) posted Change in Account Payables of -$2.0 million for Q1 2023, down 140.09% sequentially from $5.0 million in Q4 2022, and down 40.36% YoY from -$3.4 million in Q1 2022.
Analysis
Mesoblast (MESO) Change in Account Payables (2014 - 2024) Analysis & Trends
Mesoblast has reported Change in Account Payables for 8 years, with the latest figure at -$2.0 million in Q1 2023.
- Quarterly Change in Account Payables fell 40.36% year-over-year to -$2.0 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $4.7 million (up 222.13% YoY) and the FY2022 annual result came in at $4.8 million, up 194.39% from the prior year.
- Change in Account Payables declined to -$2.0 million in Q1 2023 per MESO's latest filing, from $5.0 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.2 million in Q4 2019 and troughed at -$7.3 million in Q1 2019.
- A 5-year average of -$501411.8 and a median of -$1.4 million in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 1346.12% in 2021, down 1022.58% in 2021.
- Over 5 years, Change in Account Payables stood at $6.2 million in 2019, then slumped by 106.63% to -$412000.0 in 2020, then surged by 1346.12% to $5.1 million in 2021, then declined by 2.69% to $5.0 million in 2022, then plunged by 140.09% to -$2.0 million in 2023.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$2.0 million, $5.0 million, and -$2.4 million for Q1 2023, Q4 2022, and Q3 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -12.38 Mn |
| Jun 30, 2023 | -398,000.00 |
| Mar 31, 2023 | -2.00 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | -2.39 Mn |
| Jun 30, 2022 | 4.09 Mn |
| Mar 31, 2022 | -1.43 Mn |
| Dec 31, 2021 | 5.13 Mn |
| Sep 30, 2021 | -3.02 Mn |
| Jun 30, 2021 | -4.53 Mn |
| Mar 31, 2021 | -3.72 Mn |
| Dec 31, 2020 | -412,000.00 |
| Sep 30, 2020 | 3.60 Mn |
| Mar 31, 2020 | 6.31 Mn |
| Dec 31, 2019 | 5.91 Mn |
| Sep 30, 2019 | -300,000.00 |
| Mar 31, 2019 | -7.34 Mn |
| Dec 31, 2018 | 8.77 Mn |
| Sep 30, 2018 | 2.19 Mn |
| Jun 30, 2018 | -2.92 Mn |